Pemfexy Injection
Product Images NDC 71390-250

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Pemfexy (NDC 71390-250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Acacia Pharma, Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Pemfexy Figure 01)

Chemical Structure (Pemfexy Figure 01)
Chemical structure diagram of pemetrexed, the active ingredient in Pemfexy injection. The structure shows the molecular arrangement of pemetrexed, including rings and functional groups typical of this compound.*
FDA Label Image

Figure 1 (Pemfexy Figure 02)

Figure 1 (Pemfexy Figure 02)
A survival curve chart depicting overall survival percentage over time in months, with two treatment arms labeled P+P+C (black line) and P+C (gray line). The chart includes the number of patients at risk at various time points below the x-axis. The y-axis represents overall survival percentage from 0 to 100%, and the x-axis represents time in months up to 21 months.*
FDA Label Image

Figure 2 (Pemfexy Figure 03)

Figure 2 (Pemfexy Figure 03)
A survival probability Kaplan-Meier curve comparing two treatment groups: Pemetrexed plus Cisplatin (solid line) and Gemcitabine plus Cisplatin (dotted line). The x-axis shows survival time in months (0 to 30), and the y-axis shows survival probability (0.0 to 1.0). Below the graph is a table listing the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 3 (Pemfexy Figure 04)

Figure 3 (Pemfexy Figure 04)
A survival probability Kaplan-Meier curve comparing two chemotherapy regimens over 30 months. One line represents Pemetrexed plus Cisplatin (PC) and the other Gemcitabine plus Cisplatin (GC). The horizontal axis shows survival time in months, and the vertical axis shows survival probability from 0 to 1. Patient count at risk for each time point is listed below the graph for both groups.*
FDA Label Image

Figure 4 (Pemfexy Figure 05)

Figure 4 (Pemfexy Figure 05)
A survival probability graph comparing two treatment groups: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The x-axis shows survival time in months up to 30 months, and the y-axis shows survival probability from 0 to 1. The chart includes a table below listing the number of patients at risk over time for both groups.*
FDA Label Image

Figure 5 (Pemfexy Figure 06)

Figure 5 (Pemfexy Figure 06)
A survival probability Kaplan-Meier curve comparing Pemetrexed injection at 25 mg/mL versus placebo over survival time in months, showing higher survival probability for Pemetrexed. The chart includes the number of patients at risk for each treatment group at various time points up to 42 months.*
FDA Label Image

Figure 6 (Pemfexy Figure 07)

Figure 6 (Pemfexy Figure 07)
A Kaplan-Meier survival curve comparing survival probability over time in months for patients treated with Pemetrexed versus placebo. The solid line represents Pemetrexed, showing higher survival probability over time than the dotted line for placebo. Below the graph is a table of patients at risk for each group at various time points.*
FDA Label Image

Figure 7 (Pemfexy Figure 08)

Figure 7 (Pemfexy Figure 08)
A survival probability curve comparing pemetrexed injection versus placebo over a period up to 42 months. The solid line represents pemetrexed and the dotted line represents placebo. Below the graph, a table shows the number of patients at risk at various monthly intervals for both treatment groups.*
FDA Label Image

Figure 8 (Pemfexy Figure 09)

Figure 8 (Pemfexy Figure 09)
A Kaplan-Meier survival curve comparing survival probability over time in months between patients treated with pemetrexed and placebo. The solid line represents pemetrexed, and the dotted line represents placebo. Below the graph, a table lists the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 9 (Pemfexy Figure 10)

Figure 9 (Pemfexy Figure 10)
A Kaplan-Meier survival curve graph displaying survival probability over survival time in months, comparing two groups: Pemetrexed plus Cisplatin versus Cisplatin alone. The graph includes a table below showing the number of patients at risk at various time points for each group.*
FDA Label Image

25mg/ml Vial Label (Pemfexy Figure 11)

25mg/ml Vial Label (Pemfexy Figure 11)
Label for Pemfexy (pemetrexed injection) 500 mg/20 mL (25 mg/mL) multi-dose vial. The sterile cytotoxic agent is for intravenous infusion after dilution. Label includes handling precautions, dosing recommendation, storage instructions, distributor address (Acacia Pharma, Indianapolis, IN), and a barcode.*
FDA Label Image

25mg/ml Vial Label (Pemfexy Figure 12)

25mg/ml Vial Label (Pemfexy Figure 12)
Label for Pemfexy (pemetrexed injection) 500 mg/20 mL (25 mg/mL) multi-dose vial, an intravenous injection. The label includes cautions indicating it is a cytotoxic agent and provides storage and handling instructions. Distributed by Acacia Pharma, Ltd., the label also shows the NDC 71390-250-02 and includes barcode and safety advice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.